Myasthenia Gravis Foundation of America (MGFA) Scientific Session at AANEM, 2024

Developing needs-driven medical education for healthcare professionals in myasthenia gravis

Switching to subcutaneous zilucoplan from IV complement component 5 inhibitors in myasthenia gravis: A Phase 3b study

Non-steroidal immunosuppressant therapy changes during treatment with zilucoplan in patients with generalized myasthenia gravis: 120-week follow-up of RAISE-XT

Concomitant use of zilucoplan with intravenous immunoglobulin or plasma exchange during RAISE and RAISE-XT

Corticosteroid dose tapering during treatment with zilucoplan in patients with generalized myasthenia gravis: 120-week follow-up of RAISE-XT

Long-term safety and efficacy of zilucoplan in generalized myasthenia gravis: 120-week interim analysis of RAISE-XT

Rozanolixizumab treatment patterns in patients with generalized myasthenia gravis: Post hoc analysis

Effect of rozanolixizumab on myasthenia gravis-specific outcome subdomain scores: Post hoc analyses from the Phase 3 MycarinG study

Self-administration of subcutaneous rozanolixizumab in patients with generalized myasthenia gravis: Clinical study design

Rozanolixizumab in patients aged ≥65 years with generalized myasthenia gravis: A post hoc analysis of the Phase 3 MycarinG study